drugset / Trial / NCT01471340

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)

NCT01471340 ↗

Phase 4 Completed 11744 enrolled Organon and Co
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test the safety of DULERA. DULERA is a pressurized metered-dose inhaler (MDI) that contains two drugs combined, namely mometasone and formoterol in a single inhaler. Mometasone is an inhaled corticosteroid (ICS), which reduces the inflammation in the airways. Formoterol is a long-acting beta 2 agonist (LABA), which helps to relax the muscles of the airways in the lungs, making it easier to breathe. In combination, mometasone and formoterol are used for the treatment of asthma. This study will evaluate whether participants taking a LABA in combination with an ICS in a single inhaler have a different risk of having serious asthma events (hospitalization, intubation and death) compared to participants taking an ICS alone. The primary safety hypothesis is that the time-to-first serious asthma outcome (SAO) with mometasone furoate/formoterol (MF/F) MDI twice daily (BID) is non-inferior to that with mometasone furoate (MF) MDI BID in adolescents and adults with persistent asthma. If non-inferiority is achieved, the key secondary safety hypothesis of superiority of MF/F over MF will be assessed.

Timeline

Start
2012-01-09
Primary completion
2016-11-30
Completion
2016-11-30

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper The addition of formoterol to mometasone furoate maintenance therapy did not increase the risk of serious asthma-related events PMID 30537475 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 5 ug Inhaled
Subject Mometasone furoate Other / unclassified 100 ug Inhaled
Subject Mometasone furoate Other / unclassified 200 ug Inhaled
Background Prednisolone Other / unclassified — Oral
Background Prednisone Other / unclassified — Oral
Background Salbutamol Unknown 90 ug Inhaled

Indications